XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP).
XmAb 5592 (0-1000 ng/mL) enhances antibody-dependent cellular cytotoxicity (ADCC) and ntibody dependent cellular phagocytosis (ADCP) against multiple myeloma (MM) cells. XmAb 5592 significantly augments ADCC relative to the IgG1 analog against all cell lines ranged from 5-27 ng/mL, also augments antibody dependent cellular phagocytosis (ADCP) by macrophages[1].XmAb 5592 (0-10000 ng/mL) induces strong MM cell lysis by degranulation of NK cells even in the presence of bone marrow stromal cells (BMSCs)[1].
XmAb 5592 (0.3-9 mg/kg; i.p.; twice weekly for 7 doses; SCID mice with palpable RPMI8226 tumors) inhibits tumor growth in mice bearing human MM xenografts via FcγR-dependent mechanisms[1].
References:
[1]. Tai YT, et, al. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012 Mar 1;119(9):2074-82.